Skip to main content
. Author manuscript; available in PMC: 2010 Nov 1.
Published in final edited form as: Cancer Prev Res (Phila). 2009 Oct 20;2(11):957–965. doi: 10.1158/1940-6207.CAPR-09-0093

Table 1.

Patient Characteristics

Variable HNSCC cases with progression (n=15) HNSCC cases without progression (n=16) P

Age, y
 Median (range) 66.6 (53.9, 81.0) 64.7 (45.1, 79.1) 0.64 (Wilcoxon)
 Mean ± SD 66.2 ± 8.9 64.2 ±10.9 0.57 (t-test)

Gender, n (%) 0.70 (Fisher’s exact test)
 Male 11 (73.3) 10 (62.5)
 Female 4 (26.7) 6 (37.5)

Tobacco use at time of sample collection, n (%) 0.70
 Current 4 (26.7) 6 (37.5)
 Former 11(73.3) 10 (62.5)

Pack year exposure*
 Median (range) 28.1 (2, 100.5) 25.0 (2.5, 80.0) 0.88
 Mean ± SD 30.2 ± 28.6 28.2 ± 22.7 0.84

Tobacco use during follow-up, n (%) 0.23
Yes 2 (13.3) 0 (0)
No 13 (86.7) 16 (100)

Aspirin use before urine collection, n (%) 0.69
Yes 4 (26.7) 3(18.8)
No 11 (73.3) 13 (81.2)

Aspirin use during follow-up, n (%) 1.00
Yes 2 (13.3) 2 (12.5)
No 13 (86.7) 14 (87.5)
*

Excludes 1 pipe smoker in both groups